EFPIA
Europe's pharmaceutical sector is stepping up measures to help deliver faster, more equitable access to medicines for millions of patients across the EU.
The new pledge from the European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies should drastically increase the availability of innovative medicines in EU countries and decrease the time patients must wait for new medicines by several months.
From today EFPIA Member companies commit to file for pricing and reimbursement in all EU countries as soon as possible and no later than 2 years from the central EU market authorisation, provided that local systems allow it. The commitment is designed to help deliver faster, more equitable access to medicines for patients across Europe.
Data published by EFPIA last week showed that disparities in the time it takes for patients to access new medicines in different EU Member States are increasing. Patients in Germany wait around 133 days to access new medicines compared to patients in Romania that endure a wait of 899 days. Significant disparities also occurred in terms of availability of innovative medicines since less than 30% of centrally approved products are available in smaller and Eastern European Member States compared with 92% in Germany and 46% in average in the European Union.
Modelling by IQVIA predicts that the commitment to file would increase the availability of medicines from 18% up to 64% in several countries depending on the country’s payer resource for assessment of the increased number of applications. Critically, the modelling also estimates that the commitment would reduce the time patients wait for new medicines by 4 to 5 months in several countries such as Bulgaria (-179 days), Poland (-129 days) and Romania (-155 days).
However, the time between getting marketing authorisation and companies filing for pricing and reimbursement in a country is just one part of the story. According to analysis by Charles River Associates , there are 10 inter-related factors that cause barriers and delays in patients getting access to new medicines. These causes are rooted in Member States’ access systems and processes and their corresponding impact on commercial decision-making.
This is why the commitment to file is supported by the launch of an online portal where marketing authorisation holders can provide timely information regarding the timing and processing of pricing and reimbursement applications in the EU-27 countries. Bringing greater transparency to the barriers and delays to access will facilitate finding solutions in partnership. Further details of both the commitment to file and the online portal are included in Addressing patient inequalities in Europe , a position paper published by EFPIA today.
In addition to a more equitable system for patients, EFPIA is opening discussions on a more equitable system for EU Members States where the price of innovative medicines can vary between countries depending on their economic level and ability to pay. Also published today, a discussion document entitled ‘A Shared Approach to Supporting Equity-based Tiered Pricing’ sets out the key features of an equity-based tiered pricing system, anchored in the principle of solidarity between Member States and enshrined in the EU treaties. To deliver an equity based, fairer system requires the Commission and Member States to amend external reference pricing systems and undertake mechanisms to prevent the unintended consequences from internal trade in medicines.
Speaking about the launch of the new commitments, EFPIA Director General Nathalie Moll said. “By reducing the time it takes to file for pricing and reimbursement in all 27 EU member States, by bringing greater transparency to the barriers and delays to access, by co-creating an equity-based pricing system, by adopting an efficient system of EU assessments of relative efficacy and by sharing information on the implementation of novel pricing mechanisms, we believe that together we can create a step-change in the access landscape for patients across Europe. ”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220410005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets to Bring Starlink High-Speed Connectivity to Fleet10.12.2025 15:05:00 CET | Press release
The agreement between the two companies will bring reliable Wi-Fi connectivity to one of the world’s largest fleets of jets, ensuring a seamless, best-in-class experience for Owners NetJets, the global leader in private aviation, and Starlink have entered into an agreement to bring high-speed in-flight connectivity to 600 aircraft across NetJets’ global fleet by the end of 2026, unlocking a new level of productivity and exceptional travel experiences in the air. “This agreement with Starlink positions NetJets to continue delivering exceptional travel experiences for our Owners and their guests,” said Patrick Gallagher, President, NetJets Aviation. “With Starlink, travel is elevated with reliable connectivity whether our Owners are flying for business or leisure—as seamless connectivity is critical to the experience our Owners need and deserve.” This multi-year, service level agreement paves the way for NetJets to quickly and seamlessly outfit its aircraft across the U.S. and Europe, wi
Mercator Ocean International Makes AI Ocean Forecasting Operational with GLONET Validated by OceanBench at NeurIPS 202510.12.2025 15:00:00 CET | Press release
New benchmark sets the first science-based quality standard for AI ocean models, enabling GLONET’s operational deployment At NeurIPS 2025, one of the world’s leading AI conferences, Mercator Ocean unveiled OceanBench, the first open benchmark designed to assess AI Ocean forecasting models. This milestone follows the publication of Mercator Ocean’s AI model GLONET in September. Together, OceanBench and GLONET represent a decisive step toward integrating artificial intelligence into operational ocean forecasting, strengthening Europe’s leadership in trustworthy, AI-driven predictions at global scale. Presented by Anass El Aouni, Oceanographer and machine learning (ML) researcher, and Quentin Gaudel, ML Systems Architect, OceanBench establishes a unified standard to evaluate AI models against fundamental ocean dynamics. GLONET is the first forecasting system to be validated through OceanBench for operational use. Anass El Aouni : “OceanBench provides a transparent standard to evaluate AI-
Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers10.12.2025 15:00:00 CET | Press release
The collaboration seeks to study gut-brain connections in neurological disorders Baszucki Group today announced an expanded commitment to the landmark Cleveland Clinic Brain Study. Launched in 2022, this ambitious longitudinal study plans to follow healthy individuals over a 20-year period with the goal of identifying early disease markers and therapeutic targets needed to prevent and ultimately cure neurological diseases. The commitment from Baszucki Group brings their total donation to the study to $450,000. The commitment was announced at Keep Memory Alive’s annual Summer Festival & Rodeo at Shakespeare Ranch in Glenbrook, Nevada, an event benefiting the Lou Ruvo Center for Brain Health and hosted by Larry and Camille Ruvo, co-founders of Keep Memory Alive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208681513/en/ Baszucki Group and Cleveland Clinic Neurological Institute expand impact of landmark brain study to inv
CSG Xponent Sweeps Up Top-Tier Analyst, Industry Recognition for Customer Journey Management, Analytics10.12.2025 14:30:00 CET | Press release
Independent evaluations from QKS Group, FinTech Futures and CMP Research validate CSG Xponent as a driver of real-time journey orchestration and analytics CSG® (NASDAQ: CSGS) today announced that its flagship customer engagement platform, CSG Xponent, has earned multiple honors for journey management, customer analytics and personalization. This third-party recognition underscores the strength of CSG Xponent as a full-service engagement platform – one that seamlessly combines in-depth journey analytics with real-time orchestration. In the past month alone, CSG Xponent has been named: A Leader in QKS Group’s SPARK Matrix™: Customer Journey Management, 2025. Winner for “Best Personalisation and User Experience Solution” in the FinTech Futures 2025 Banking Tech Awards. A Core Performing provider in CMP Research’s Prism for Customer Analytics. “CSG Xponent moves beyond broad segmentation to pinpoint each customer’s journey state, whether stalled, at-risk or ready to convert, and then quant
AI Power Surge and Energy Transition Push Global Project Finance into a New Era10.12.2025 14:30:00 CET | Press release
70% of finance professionals expect infrastructure to drive the strongest growth, followed by renewables (48%) and TMT (43%).53% now view private equity as a primary source of equity funding, signaling a major shift in capital dynamics.80% cite KYC requirements as the top execution challenge amid rising deal complexity. Global project finance is entering a transformative era, driven by soaring demand for energy capacity, accelerated digitalization and large-scale infrastructure upgrades, reshaping investment priorities worldwide. These insights come from new research commissioned by CSC, based on responses from 200 project finance professionals, revealing a market shifting toward more complex, capital-intensive projects and a greater reliance on private capital. CSC’s latest report, Project Finance at an Inflection Point: Adapting to New Realities1, reveals a sector that is rapidly expanding in both scale and complexity driven by capital increasingly targeting long-term, strategically
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom